openPR Logo
Press release

Generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market

07-24-2018 10:12 AM CET | Health & Medicine

Press release from: Future Market Insights

Generic and branded anticonvulsants are restraining the growth

Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used in treatment of bipolar disorder and in neuropathic pain management.

Anyone could potentially have a single epileptic seizure at some point in their lives. This is not the same as having epilepsy, which is a tendency to have seizures that start in the brain. Epilepsy can affect people of any age group. Though brain injury, brain cancer, drug and alcohol misuse and stroke are some of the reasons for epileptic seizures, the exact reason for convulsions is not known. Some of the common symptoms which occur before convulsions include, visual loss, strange feeling, nausea, numbness in body parts, headache and racing thoughts.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1337

Anticonvulsants Market: Drivers and Restraints

Increasing awareness about the anticonvulsants available in the market, patent expiration of many blockbuster drugs are some of the major factors that are driving the global anticonvulsants market towards growth. There are now 24 antiepileptic drugs (AEDs) approved for use in epilepsy in the US by FDA. Moreover, three trends involving consumption of AEDs have become clinically important and must be considered by all who treat patients with epilepsy. These trends include issues of generic substitution of AEDs, pharmacogenomics predicting serious adverse events in certain ethnic populations, and the issue of the suicide risk involving the entire class of AEDs. While, high costs and unavailability of convenient dosage forms of both generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market.

Anticonvulsants Market: Segmentation

Anticonvulsants market is segmented based on product type, application, end user and geography.

Based on product type, the anticonvulsants market is segmented as follows:

Barbiturates

Aldehydes

Benzodiazepines

Aromatic allylic alcohols

Carboxamides

Bromides

Carbamates

Sulfonamides

Fructose derivatives

Pyrrolidines

Triazines

Fatty acids

Oxazolidinediones

Ureas

GABA analogs

Propionates

Hydantoins

Pyrimidinediones

Valproylamides (amide derivatives of valproate)

Others

Based on application, the anticonvulsants market is segmented as follows:

Epilepsy

Fibromyalgia

Migraine

Neuropathic pain

Bipolar disorder

Anxiety

Borderline personality disorder

Based on end user, the anticonvulsants market is segmented as follows:

Hospitals

Clinics

Ambulatory surgical clinics

Anticonvulsants Market: Overview

Seizures are expected to result in physical, psychological and social repercussions. People with epilepsy could adhere rigorously to their medication regimes in order to prevent these deleterious outcomes. Treatment of epileptic seizures has led to the growth of anticonvulsants market. Barbiturates were the first antiepileptic drugs. These are more effective and tolerable than bromides. Hydantoins are the first to be known as modern antiepileptic drugs. Succinimides are an old group of drug which are rarely prescribed nowadays. Consequently with these antiepileptic or antiseizure drugs, anticonvulsants market is growing immensely leaving a significant impact on the treatment of epileptic seizures. The antiepileptic drug market is threatened by generic completion, which has been increasing dramatically in the face of patent expirations among several of the major branded antiepileptics. However, there have been cases where generic antiepileptic drugs have not been as efficacious as their branded counterparts have.

Anticonvulsants Market: Region-wise Outlook

Region wise, the global anticonvulsants marketis classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. Currently, North America dominates the anticonvulsants market followed by Europe. Asia-Pacific is expected to emerge as a lucrative region, owing to factors such as increasing healthcare spending, improving healthcare infrastructure, and increasing demand for drugs. Given these factors, the market for anticonvulsants is likely to grow rapidly in Asia-Pacific region.

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-1337

Anticonvulsants Market: Key Players

Some of the key players, contributing to global anticonvulsants drug market, are Johnson & Johnson (J&J), Novartis AG, UCB Group, GlaxoSmithKline plc, Pfizer Inc., Abbott Laboratories, Cephalon Inc. and Shire plc. Pfizer has been estimated to cover the largest market share in the antiepileptic market, accounting for close to one-third of total revenues of the market with it two leading brands.

About Us
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web:https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Generic and branded anticonvulsants are restraining the growth of novel therapies in the anticonvulsants market here

News-ID: 1142008 • Views:

More Releases from Future Market Insights

Encapsulant Market Poised for Significant Growth, Projected to Reach USD 9.5 Billion by 2034 | FMI
Encapsulant Market Poised for Significant Growth, Projected to Reach USD 9.5 Bil …
The global Encapsulant Market is poised for substantial expansion, with an expected valuation of USD 4.1 billion in 2024. The rising adoption of encapsulants in solar panels, electronics, and automotive applications is significantly driving demand. Encapsulants play a crucial role in enhancing durability, reliability, and efficiency by providing protective coatings against environmental damage, thereby extending the lifespan of devices. Market growth is further supported by advancements in encapsulant materials, including ethylene
Energy Recovery Ventilator Core Market Share Set to Reach USD 2.5 billion by 2034: Key Drivers and Trends | FMI
Energy Recovery Ventilator Core Market Share Set to Reach USD 2.5 billion by 203 …
The global energy recovery ventilator core market size is poised to reach a valuation of USD 1.1 billion by 2024, driven by partnerships with energy service companies. This trend is set to unlock new avenues for market growth, with a projected CAGR of 8.1% between 2024 and 2034, culminating in a total valuation of around USD 2.5 billion by 2034. The increasing frequency and severity of extreme weather events attributed to
Phosphorus-Enriched Organic Manure Market Set to Surge: Projected Growth to Reach USD 6,347.6 million by 2034 | FMI
Phosphorus-Enriched Organic Manure Market Set to Surge: Projected Growth to Reac …
The global phosphorus-enriched organic manure market size is expected to grow significantly, with its value increasing from USD 3,382.9 million in 2024 to USD 6,347.6 million by 2034. This growth corresponds to a CAGR of 6.5% over the forecast period. The rising demand for environmentally friendly organic products is driving the market for phosphate-rich organic manure (PROM). As awareness of sustainable farming practices and the need to reduce the chemical load
India Methylamine Market Poised for Significant Growth: Revenue to Expand Around 2.2X Through 2034 | FMI
India Methylamine Market Poised for Significant Growth: Revenue to Expand Around …
The India methylamine industry has experienced remarkable growth over the past decade, with its market size reaching USD 68.3 million in 2023. The demand for methylamine, a critical precursor in multiple industries, is projected to take the overall valuation to USD 159.2 million by 2034, expanding at a CAGR of 8.0%. The increasing applications of methylamine in pharmaceuticals, agrochemicals, and other industrial processes have been instrumental in driving this growth. Key

All 5 Releases


More Releases for Anticonvulsants

Anticonvulsants Market Therapeutic Survey Reviews, Analysis 2025
The report titled “Anticonvulsants Market” report will be very useful to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, SWOT analysis, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts. The Anticonvulsants market was valued at
Anticonvulsants for Neuropathic Pain Market unprovoked by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants Market Opportunities and Forecast Assessment,2016-2026
Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used
Anticonvulsants Drug Market - Significant Growth During 2025
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and
Anticonvulsants Market Growth, Forecast and Value Chain 2016-2026
Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used
Anticonvulsants Drug Market: Upcoming Demands and Growth Analysis
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and